Sponsor-Investigator Receives Warning Letter for Failing to Submit an IND

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson FDA Compliance Expert Suite, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

Sponsor-Investigator Receives Warning Letter for Failing to Submit an IND

J.W. Schomisch

March 17, 2023 at 02:39 PM EST

The FDA issued a Warning Letter to a sponsor-investigator for allegedly failing to submit an Investigational New Drug (IND) application for the conduct of a clinical investigation. The March 3 letter to Maggie Jeffries, M.D., with Avanti Anesthesiology, LLC in Houston was the result of a Bioresearch Monitoring program inspection between July 19 and Aug. 5, 2021. In an Aug. 1... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

Sponsor-Investigator Receives Warning Letter for Failing to Submit an IND

My Research Folders

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT